Literature DB >> 15330917

Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

Pablo C Okhuysen1, Zhi Dong Jiang, Lily Carlin, Charles Forbes, Herbert L DuPont.   

Abstract

OBJECTIVES: Irritable bowel syndrome (IBS) has been reported to complicate bacterial diarrhea. Because of the frequency of international travel and the common occurrence of bacterial diarrhea, we studied the occurrence of chronic gastrointestinal complaints and post-diarrhea IBS in North U.S. travelers to Mexico.
METHODS: One hundred and sixty-nine healthy students were followed prospectively for 5 wk for the occurrence and etiology of diarrhea while studying for 5 wk in Mexico. Subjects recorded their symptoms during travel and completed a gastrointestinal symptom questionnaire 6 months after returning to the United States to determine the presence of IBS using the Rome II criteria.
RESULTS: Ninety-seven (57%) subjects returned a completed questionnaire. Sixty-one (63%) developed diarrhea while in Mexico, mostly due to enterotoxigenic and enteroaggregative Escherichia coli. Six months after travel the following chronic symptoms were reported: loose stools, abdominal pain, and fecal urgency in 17 (18%), 17 (18%), and 9 (9%) respectively. Of the 60 patients surveyed who had acquired diarrhea in Mexico, 7 (11%) met the criteria for IBS 6 months later of which 6 (10%) were newly diagnosed. No identified pathogen in the initial illness was associated with the development of IBS.
CONCLUSIONS: Chronic gastrointestinal complaints including IBS are common in returning travelers having experienced diarrhea. Postinfectious complications of traveler's diarrhea require further study for etiology and strategy for prevention.

Entities:  

Mesh:

Year:  2004        PMID: 15330917     DOI: 10.1111/j.1572-0241.2004.30435.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  57 in total

1.  Management of the returning traveler with diarrhea.

Authors:  Philippe P H de Saussure
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 2.  Prevention and self-treatment of traveler's diarrhea.

Authors:  David J Diemert
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 3.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

Review 4.  Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.

Authors:  Uday C Ghoshal; Kok-Ann Gwee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

5.  Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.

Authors:  Mark Pimentel; Sheila Lezcano
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 6.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

7.  Epidemiology and self-treatment of travelers' diarrhea in a large, prospective cohort of department of defense beneficiaries.

Authors:  Tahaniyat Lalani; Jason D Maguire; Edward M Grant; Jamie Fraser; Anuradha Ganesan; Mark D Johnson; Robert G Deiss; Mark S Riddle; Timothy Burgess; David R Tribble
Journal:  J Travel Med       Date:  2014-12-07       Impact factor: 8.490

Review 8.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 9.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.